Posts Tagged


Jan 2021

ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients

Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Dec 2020

BenevolentAI wins Innovation Award at 2020 Scrip Awards

BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Nov 2020

Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality

Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 2020

Investival Showcase Virtual w/ Jackie Hunter

Join BenevolentAI’s Board Director, Jackie Hunter, at the Investival Showcase for a discussion of cross-sector approaches to solving healthcare’s biggest challenges.